Table 1.
Distribution of patient demographic and disease characteristics in Induction and Consolidation
| Conjugated hyperbilirubinemia (n=15) | No conjugated hyperbilirubinemia (n=358) | P value | |
|---|---|---|---|
| Median Age in Years (IQR) | 14.0 (10.9–15.5) | 6.3 (3.5–11.9) | 0.0001 |
| Ethnicity, n (%) | 0.044 | ||
| Hispanic | 12 (80.0) | 192 (53.6) | |
| Non-Hispanic | 3 (20.0) | 166 (46.4) | |
| Sex, n (%) | 0.901 | ||
| Male | 9 (60.0) | 209 (58.4) | |
| Female | 6 (40.0) | 149 (41.6) | |
| BMI at Diagnosis, n (%) | <0.001 | ||
| <95th Percentile | 4 (26.7) | 282 (84.4) | |
| ≥95th Percentile | 11 (73.3) | 52 (15.6) | |
| ALL Induction Type, n (%) | 0.002 | ||
| Three-drug induction1 | 1 (6.7) | 169 (47.2) | |
| Four-drug induction2 | 14 (93.3) | 189 (52.8) | |
| MRD Status (NCI HR B-ALL patients only) | 0.759 | ||
| <0.01% | 10 (76.9) | 96 (71.1) | |
| ≥0.01% | 3 (23.1) | 39 (28.9) |
1
Three-drug induction includes oral dexamethasone, intravenous vincristine, and intramuscular or intravenous pegaspargase
2
Four-drug induction in oral dexamethasone (age <10 years) or prednisone (age ≥10 years), intravenous vincristine, and intramuscular or intravenous pegaspargase, and intravenous daunorubicin